Pharma Impact: Health, Economic, and Access Insights
Facts and data are the bedrock of informed health policy and decisions. They provide an objective and evidence-based foundation upon which policymakers, healthcare professionals, and individuals can make choices that promote better health outcomes.
GlobalData conducts research that informs government and payer policy on value-based healthcare and improving access to treatment. The reports available here for download, along with links to other published studies, share the common goal of demonstrating how strategic interventions can reduce medical costs, increase productivity, improve quality of life, lower mortality rates, address health inequities, and optimize pricing, reimbursement, and access strategies. The latest white paper on drug shortages (below) explores the root causes, policy responses, and strategic recommendations to enhance access and mitigate future supply disruptions. Additional studies on the economic burden of obesity and the value of treatment can be found here. For more information, contact Consulting@globaldata.com.
GlobalData Reports
Model documentation and policy analyses from the GlobalData health economics team.
Model Documentation
Disease Prevention and Treatment Microsimulation Model: Documentation
Technical documentation for GlobalData’s Disease Prevention and Treatment Microsimulation Model (DPTMM), covering model structure, data sources, and the methods used to project health outcomes and medical costs.
Report
Impact and Health Equity Implications of Copayment Drug Benefits
An analysis of how copayment-based drug benefit designs affect patient out-of-pocket costs, medication use, and health outcomes, and how those effects differ across populations.
Published Evidence
Peer-reviewed studies on the value of treating obesity for the payers who fund care, linked to their original publications.
Nutrition & Diabetes · 2024
Impact on Employers
Estimates the health and economic benefits to employers of covering obesity treatment for their workforce, including medical savings and productivity gains.
Diabetes Care · 2025
Impact for Medicaid
Weighs the benefits and costs of treating obesity among Medicaid enrollees, projecting effects on health outcomes and program spending.
Conference Poster
Presented at ISPOR · Poster EPH236
Rapid Access to Innovative Cancer Treatments Saves Lives
Microsimulation Modeling Across Multiple Myeloma, Colorectal Cancer, and Non-Small Cell Lung Cancer
Authors: Anna Moody, Owen Parker, Tim Dall, Tatiana Kolesnikova, Tanvi Sapra, GlobalData Healthcare
Quantifies the survival US patients gain from earlier access to novel cancer therapies compared with EU5 timelines, where approval and HTA reimbursement delays hold back access by 15 to 20 months. Patients who switched to a superior therapy under US timelines gained 3.3 to 4.3 months of survival on average, and up to 10.9 months in dMMR/MSI-H colorectal cancer.
~7,458 life-years preserved annually across US patients with MM, NSCLC, and CRC
Summaries above are drawn from the linked publications and are presented for informational purposes. Refer to each original article for full methodology, populations studied, assumptions, and limitations before citing or applying these findings.